Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer

Clinical Colorectal Cancer

Volumn 14, Issue 4, 2015, Pages 203-218

  Lee, Michael S ^a   Kopetz, Scott ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cetuximab; HER2; MET; Panitumumab; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; ROUS SARCOMA ONCOGENE CELLULAR HOMOLOG; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC THERAPY; BIOLOGY; DRUG RECHALLENGE; ENZYME INHIBITION; GENE MUTATION; GENETIC SCREENING; HUMAN; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE K RAS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG DESIGN; DRUG RESISTANCE; METABOLISM; METASTASIS; PATHOLOGY; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84947870575     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2015.05.006     Document Type: Review

References (137)

1. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute, 2014. Available at: http://seer.cancer.gov/csr/1975-2011. Accessed Sept 19, 2014.
2. S. Kopetz, G.J. Chang, M.J. Overman, and et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 2009 3677 3683
3. E. Van Cutsem, C.H. Kohne, I. Lang, and et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
4. C. Bokemeyer, I. Bondarenko, J.T. Hartmann, and et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 2011 1535 1546
5. T.S. Maughan, R.A. Adams, C.G. Smith, and et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
6. J.Y. Douillard, K.S. Oliner, S. Siena, and et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
7. R.G. Amado, M. Wolf, M. Peeters, and et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
8. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, and et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
9. N. Normanno, A. De Luca, C. Bianco, and et al. Epidermal growth factor receptor (EGFR) signaling in cancer Gene 366 2006 2 16
10. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
11. J.T. Jones, R.W. Akita, and M.X. Sliwkowski Binding specificities and affinities of EGF domains for ErbB receptors FEBS Lett 447 1999 227 231
12. N. Normanno, S. Tejpar, F. Morgillo, A. De Luca, E. Van Cutsem, and F. Ciardiello Implications for KRAS status and EGFR-targeted therapies in metastatic CRC Nat Rev Clin Oncol 6 2009 519 527
13. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
14. N.I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin Cancer Res 1 1995 1311 1318
15. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang, C.G. Davis, and A. Jakobovits Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy Cancer Res 59 1999 1236 1243
16. S. Li, K.R. Schmitz, P.D. Jeffrey, J.J. Wiltzius, P. Kussie, and K.M. Ferguson Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 2005 301 311
17. J. Kurai, H. Chikumi, K. Hashimoto, and et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines Clin Cancer Res 13 2007 1552 1561
18. T.J. Price, M. Peeters, T.W. Kim, and et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study Lancet Oncol 15 2014 569 579
19. K.Y. Chung, J. Shia, N.E. Kemeny, and et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 2005 1803 1810
20. J.R. Hecht, E. Mitchell, M.A. Neubauer, and et al. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer Clin Cancer Res 16 2010 2205 2213
21. C. Bokemeyer, I. Bondarenko, A. Makhson, and et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
22. K.M. Tveit, T. Guren, B. Glimelius, and et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study J Clin Oncol 30 2012 1755 1762
23. E. Van Cutsem, C.H. Kohne, E. Hitre, and et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
24. J.Y. Douillard, S. Siena, J. Cassidy, and et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
25. A.P. Venook, D. Niedzwiecki, H.J. Lenz, and et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) (abstract LBA3) J Clin Oncol 32 suppl 5s 2014
26. V. Heinemann, L.F. von Weikersthal, T. Decker, and et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 2014 1065 1075
27. S. Stintzing, D.P. Modest, L.F. von Weikersthal, and et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population (abstract LBA11) Ann Oncol 25 suppl 5 2014
28. B. Chibaudel, C. Tournigand, F. Bonnetain, and et al. Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer: a GERCOR randomized open-label phase III study (abstract TPS3648) J Clin Oncol 32 suppl 5s 2014
29. J. Primrose, S. Falk, M. Finch-Jones, and et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial Lancet Oncol 15 2014 601 611
30. B. Nordlinger, G.J. Poston, and R.M. Goldberg Should the results of the New EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver? J Clin Oncol 33 2015 241 243
31. D.J. Jonker, C.J. O'Callaghan, C.S. Karapetis, and et al. Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048
32. A.F. Sobrero, J. Maurel, L. Fehrenbacher, and et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2008 2311 2319
33. E. Van Cutsem, M. Peeters, S. Siena, and et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664
34. M.T. Seymour, S.R. Brown, G. Middleton, and et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial Lancet Oncol 14 2013 749 759
35. M. Peeters, T.J. Price, A. Cervantes, and et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 2010 4706 4713
36. M. Peeters, T.J. Price, A. Cervantes, and et al. Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer Ann Oncol 25 2014 107 116
37. C. Bokemeyer, C.H. Kohne, F. Ciardiello, and et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab (abstract 3505) J Clin Oncol 32 suppl 5s 2014
38. F. Ciardiello, H.J. Lenz, C.H. Kohne, and et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab (abstract 3506) J Clin Oncol 32 suppl 5s 2014
39. M. Peeters, K.S. Oliner, T.J. Price, and et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC) (abstract 3568) J Clin Oncol 32 suppl 5s 2014
40. J. Baselga, J. Cortes, S.B. Kim, and et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N Engl J Med 366 2012 109 119
41. G. Tan, J.D. Kearns, N. Gerami-Moayed, and et al. Mechanism of action of MM-151, a potent mixture of three human antibody antagonists targeting EGFR (abstract A210) Mol Cancer Ther 10 2011
42. C.H. Lieu, W.A. Harb, M. Beeram, and et al. Phase 1 trial of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors (abstract 2518) J Clin Oncol 32 suppl 5s 2014
43. M.W. Pedersen, H.J. Jacobsen, K. Koefoed, and et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy Cancer Res 70 2010 588 597
44. M. Iida, T.M. Brand, M.M. Starr, and et al. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab Neoplasia 15 2013 1196 1206
45. G. Argilés, R. Dienstmann, M.B. Viñuales, and et al. Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment (abstract 3551) J Clin Oncol 32 suppl 5s 2014
46. D. Santini, B. Vincenzi, R. Addeo, and et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol 23 2012 2313 2318
47. R.C. Wadlow, A.F. Hezel, T.A. Abrams, and et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab Oncologist 17 2012 14
48. M.W. Saif, K. Kaley, E. Chu, and M.S. Copur Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions Clin Colorectal Cancer 9 2010 315 318
49. S.C. Lau, V. Chung, D. Lim, and S. Shibata Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: a retrospective review J Oncol Pharm Pract 20 2014 83 87
50. J. Metges, J.F. Ramée, O. Dupuis, and et al. PANERB study: which category of patients, suffering from metastatic colorectal cancer, can benefit from panitumumab treatment after cetuximab-based regimen failure? (abstract 572P) Ann Oncol 23 suppl 9 2012
51. C. Montagut, A. Dalmases, B. Bellosillo, and et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer Nat Med 18 2012 221 223
52. M.P. Morelli, M. Overman, A. Dasari, and et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment Ann Oncol 26 2015 731 736
53. C. Montagut, B. Bellosillo, I. Gonzalez, and et al. Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer (abstract 3526) J Clin Oncol 32 suppl 5s 2014
54. T.J. Price, K. Newhall, M. Peeters, and et al. Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) (abstract 740) J Clin Oncol 33 suppl 3 2015
55. M.P. Morelli, M.J. Overman, E.V. Sanchez, and et al. Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients (abstract 11117) J Clin Oncol 32 suppl 5s 2014
56. C.A. Townsley, P. Major, L.L. Siu, and et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer Br J Cancer 94 2006 1136 1143
57. M.L. Rothenberg, B. LaFleur, D.E. Levy, and et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma J Clin Oncol 23 2005 9265 9274
58. P. Kozuch, S. Malamud, C. Wasserman, P. Homel, T. Mirzoyev, and M. Grossbard Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer Clin Colorectal Cancer 8 2009 38 42
59. G.A. Fisher, T. Kuo, M. Ramsey, and et al. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer Clin Cancer Res 14 2008 7074 7079
60. S. Cascinu, R. Berardi, S. Salvagni, and et al. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation Br J Cancer 98 2008 71 76
61. T. Kuo, C.D. Cho, J. Halsey, and et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer J Clin Oncol 23 2005 5613 5619
62. A. Santoro, A. Comandone, L. Rimassa, and et al. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer Ann Oncol 19 2008 1888 1893
63. A.J. Weickhardt, T.J. Price, G. Chong, and et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer J Clin Oncol 30 2012 1505 1512
64. H. Senellart, E. Samalin, A. Adenis, and et al. UCGI 25: a multicentric randomized phase II trial evaluating dual targeting of the epidermal growth factor (EGFR) using the combination of cetuximab and afatinib versus cetuximab alone in patients (pts) wih chemotherapy refractory wtRAS metastatic colorectal cancer (mCRC) (abstract TPS3666) J Clin Oncol 32 suppl 5s 2014
65. L.B. Saltz, H.J. Lenz, H.L. Kindler, and et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561
66. D. Cunningham, Y. Humblet, S. Siena, and et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
67. J.R. Hecht, E. Mitchell, T. Chidiac, and et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
68. J. Tol, M. Koopman, A. Cats, and et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
69. L.L. Siu, J.D. Shapiro, D.J. Jonker, and et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial J Clin Oncol 31 2013 2477 2484
70. T.J. Yeatman A renaissance for SRC Nat Rev Cancer 4 2004 470 480
71. S. Kopetz, D.P. Lesslie, N.A. Dallas, and et al. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress Cancer Res 69 2009 3842 3849
72. M.S. Talamonti, M.S. Roh, S.A. Curley, and G.E. Gallick Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer J Clin Invest 91 1993 53 60
73. H. Aligayer, D.D. Boyd, M.M. Heiss, E.K. Abdalla, S.A. Curley, and G.E. Gallick Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis Cancer 94 2002 344 351
74. S. Kopetz, V.K. Morris, N. Parikh, and et al. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer BMC Cancer 14 2014 660
75. D.L. Wheeler, M. Iida, T.J. Kruser, and et al. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab Cancer Biol Ther 8 2009 696 703
76. E.F. Dunn, M. Iida, R.A. Myers, and et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab Oncogene 30 2011 561 574
77. M.R. Sharma, K. Wroblewski, B.N. Polite, and et al. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium Invest New Drugs 30 2012 1211 1215
78. C. Lieu, R. Wolff, C. Eng, and et al. Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer (abstract 3536) J Clin Oncol 28 suppl 15s 2010
79. A.H. Marx, E.C. Burandt, M. Choschzick, and et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers Hum Pathol 41 2010 1577 1585
80. D.O. Kavanagh, G. Chambers, L. O'Grady, and et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 9 2009 1
81. A. Bertotti, G. Migliardi, F. Galimi, and et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer Cancer Discov 1 2011 508 523
82. D. Frank, A. Jumonville, N.K. Loconte, and et al. A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: a Wisconsin Oncology Network study J Gastrointest Oncol 3 2012 90 96
83. J.F. Deeken, H. Wang, J. Marshall, and et al. Final results of a phase I study of lapatinib (LAP) and cetuximab (CET) in patients with CET-sensitive solid tumors (abstract 2616) J Clin Oncol 31 suppl 2013
84. D.A. Rubinson, H.S. Hochster, D.P. Ryan, and et al. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients Invest New Drugs 32 2014 113 122
85. S.Q. Ashraf, A.M. Nicholls, J.L. Wilding, T.G. Ntouroupi, N.J. Mortensen, and W.F. Bodmer Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel Proc Natl Acad Sci U S A 109 2012 21046 21051
86. R.K. Ramanathan, J.J. Hwang, W.C. Zamboni, and et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial Cancer Invest 22 2004 858 865
87. J. Clark, D. Niedzwiecki, D. Hollis, and R. Mayer Phase II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzamab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy (abstract 3584) Proc Am Soc Clin Oncol 22 2003
88. S.M. Sorscher Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer Cancer Invest 29 2011 456 459
89. S. Marsoni, A. Bertotti, A. Sartore-Bianchi, and et al. Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: the HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification) (abstract TPS3648) J Clin Oncol 31 suppl 2013
90. S.P. Soltoff, K.L. Carraway 3rd, S.A. Prigent, W.G. Gullick, and L.C. Cantley ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor Mol Cell Biol 14 1994 3550 3558
91. A. Beji, D. Horst, J. Engel, T. Kirchner, and A. Ullrich Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer Clin Cancer Res 18 2012 956 968
92. E. Buck, A. Eyzaguirre, J.D. Haley, N.W. Gibson, P. Cagnoni, and K.K. Iwata Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity Mol Cancer Ther 5 2006 2051 2059
93. J.M. Cleary, A.J. McRee, B.H. O'Neil, and et al. A phase 1 study of MM-121 (a fully human monoclonal antibody targeting the epidermal growth factor receptor family member ErbB3) in combination with cetuximab and irinotecan in patients with advanced cancers (abstract 3076) J Clin Oncol 32 suppl 5s 2014
94. G. Schaefer, L. Haber, L.M. Crocker, and et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies Cancer Cell 20 2011 472 486
95. S. Huang, C. Li, E.A. Armstrong, and et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation Cancer Res 73 2013 824 833
96. A. Cervantes-Ruiperez, D. Juric, M. Hidalgo, and et al. A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: expansion cohorts (abstract 2568) J Clin Oncol 30 suppl 2012
97. C. Sun, S. Hobor, A. Bertotti, and et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 Cell Rep 7 2014 86 93
98. H. Takeuchi, A. Bilchik, S. Saha, and et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases Clin Cancer Res 9 2003 1480 1488
99. D. Liska, C.T. Chen, T. Bachleitner-Hofmann, J.G. Christensen, and M.R. Weiser HGF rescues colorectal cancer cells from EGFR inhibition via MET activation Clin Cancer Res 17 2011 472 482
100. P. Luraghi, G. Reato, E. Cipriano, and et al. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors Cancer Res 74 2014 1857 1869
101. A. Bardelli, S. Corso, A. Bertotti, and et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer Cancer Discov 3 2013 658 673
102. C. Eng, L.L. Hart, A. Severtsev, and et al. A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy (abstract 3508) J Clin Oncol 31 suppl 2013
103. A. Calles, N. Kwiatkowski, B.K. Cammarata, D. Ercan, N.S. Gray, and P.A. Janne Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines Mol Oncol 9 2015 260 269
104. R. Katayama, A. Aoyama, T. Yamori, and et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition Cancer Res 73 2013 3087 3096
105. C. Basilico, S. Pennacchietti, E. Vigna, and et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET Clin Cancer Res 19 2013 2381 2392
106. T.L. Burgess, J. Sun, S. Meyer, and et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor Mol Cancer Ther 9 2010 400 409
107. E. Van Cutsem, C. Eng, E. Nowara, and et al. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer Clin Cancer Res 20 2014 4240 4250
108. M. Merchant, X. Ma, H.R. Maun, and et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent Proc Natl Acad Sci U S A 110 2013 E2987 E2996
109. J.C. Bendell, T.J. Ervin, D. Gallinson, and et al. Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer Clin Colorectal Cancer 12 2013 218 222
110. X. Liao, T. Morikawa, P. Lochhead, and et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review Clin Cancer Res 18 2012 2257 2268
111. W. De Roock, B. Claes, D. Bernasconi, and et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
112. C.S. Karapetis, D. Jonker, M. Daneshmand, and et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17 Clin Cancer Res 20 2014 744 753
113. R. Mallon, L.R. Feldberg, J. Lucas, and et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor Clin Cancer Res 17 2011 3193 3203
114. J. Tabernero, N. Brega, C. Davis, and et al. A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC) (abstract TPS3649) J Clin Oncol 32 suppl 5s 2014
115. S. Shahda, M. Yu, J. Picus, and et al. Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102 - final report (abstract 3587) J Clin Oncol 29 suppl 2011
116. A.R. Townsend, L. Pirc, P. Cooper, and et al. A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT) (abstract e14506) J Clin Oncol 31 suppl 2013
117. B. Vogelstein, E.R. Fearon, S.R. Hamilton, and et al. Genetic alterations during colorectal-tumor development N Engl J Med 319 1988 525 532
118. N. Knijn, L.J. Mekenkamp, M. Klomp, and et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients Br J Cancer 104 2011 1020 1026
119. S. Misale, R. Yaeger, S. Hobor, and et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
120. L.A. Diaz Jr., R.T. Williams, J. Wu, and et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 2012 537 540
121. J. Bennouna, I. Lang, M. Valladares-Ayerbes, and et al. A Pphase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens Invest New Drugs 29 2011 1021 1028
122. W.A. Messersmith, G.S. Falchook, L.A. Fecher, and et al. Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer (abstract 246) J Clin Oncol 29 suppl 4 2011
123. S. Misale, S. Arena, S. Lamba, and et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer Sci Transl Med 6 2014 224ra26
124. T. Troiani, S. Napolitano, D. Vitagliano, and et al. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition Clin Cancer Res 20 2014 3775 3786
125. S. Lamba, M. Russo, C. Sun, and et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells Cell Rep 8 2014 1475 1483
126. R.B. Corcoran, K.A. Cheng, A.N. Hata, and et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Cancer Cell 23 2013 121 128
127. S. Van Schaeybroeck, M. Kalimutho, P.D. Dunne, and et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer Cell Rep 7 2014 1940 1955
128. A. Spreafico, J.J. Tentler, T.M. Pitts, and et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer Clin Cancer Res 19 2013 4149 4162
129. L. Boussemart, H. Malka-Mahieu, I. Girault, and et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies Nature 513 2014 105 109
130. R. Palmqvist, G. Hallmans, S. Rinaldi, and et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden Gut 50 2002 642 646
131. J. Ma, M.N. Pollak, E. Giovannucci, and et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3 J Natl Cancer Inst 91 1999 620 625
132. D. Sachdev, and D. Yee Disrupting insulin-like growth factor signaling as a potential cancer therapy Mol Cancer Ther 6 2007 1 12
133. M. Ii, H. Li, Y. Adachi, and et al. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status Clin Cancer Res 17 2011 5048 5059
134. C.R. Becerra, R. Salazar, R. Garcia-Carbonero, and et al. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial Cancer Chemother Pharmacol 73 2014 695 702
135. M. Broussas, J. Dupont, A. Gonzalez, and et al. Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor Int J Cancer 124 2009 2281 2293
136. D.J. Watkins, J. Tabernero, H. Schmoll, and et al. A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status (abstract 3501) J Clin Oncol 29 suppl 2011
137. D.J. Watkins, M. Ayers, D. Cunningham, and et al. Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC) (abstract 3531) J Clin Oncol 30 suppl 2012